FindTrial
Sign In

Effect of supplement (OVAZOA Reserve Tablet) in Infertile Women

Effectiveness of supplement (OVAZOATM) - Reserve tablet in infertile women with poor ovarian reserve: A Randomized, Double-blind, placebo-controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109473
Enrollment
60
Registered
2026-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N978- Female infertility of other origin

Interventions

Intervention1: OVAZOA TM: Leucine, Ubiquinol, Melatonin, Tocotrienol (Vitamin E), Zinc Acetate, Ergocalciferol (Vitamin D2), Quercetin, Nicotinamide, Selenomethionine: 800mg, 100 mg, 3 mg, 10mg, 12m

Sponsors

MMC Pharmaceuticals Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Married females aged 21 to 45 years diagnosed with infertility. 2. Women with serum anti-Mullerian hormone less than 1.5 ng/mL and antral follicle count less than 4. 3. Participants willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Participants taking antidepressants, anti-serotonin, antipsychotics, or other antipsychiatric drugs. 2. Study participants who have undergone radio/chemotherapy. 3. Participants those who received hormone therapy within 6 months. 4. Known case of polycystic ovarian syndrome.

Design outcomes

Primary

MeasureTime frame
Anti-Mullerian hormone-AMH Antral follicle counts-AFC Dehydroepiandrosterone-DHEA Timepoint: Baseline, Follow up- 12 weeks—

Secondary

MeasureTime frame
Adverse drug reaction during the study Timepoint: 1st, 2nd, 3rd month—

Countries

India

Contacts

Public ContactPooja C

SRM Institute of Science and Technology

vijayakm2@srmist.edu.in9003400350

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026